Medicare Rx Data May Be Difficult To Interpret, Merck Exec Cautions
Executive Summary
Drawing conclusions about drug safety and outcomes from Medicare prescription drug data needs to be done with caution, Merck VP-Outcomes Research & Management Marc Berger told a Centers for Medicare & Medicaid Services "Open Door Forum" June 13
You may also be interested in...
CMS Relationship With Manufacturers Has Improved, But Questions Remain
The relationship between CMS and drug manufacturers is improving through earlier communication regarding coverage decisions and emphasis on common interests, according to CMS Director-Coverage Analysis Group Steven Phurrough
CMS Relationship With Manufacturers Has Improved, But Questions Remain
The relationship between CMS and drug manufacturers is improving through earlier communication regarding coverage decisions and emphasis on common interests, according to CMS Director-Coverage Analysis Group Steven Phurrough
Blues Data May Give Employers Basis For Evidence-Based Coverage Decisions
The BlueCross BlueShield Association is considering ways to partner with the pharmaceutical industry to provide access to its newly created claims database